WaveMan
WaveMan · Company
MDAI · Spectral Ai, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MDAI Spectral AI (MDAI) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001833498
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
24
13F, latest reported quarter

Spectral AI insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Spectral AI, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
DiMaio John Michael
Director
BUY
2024-05-14 SECtraded 2024-05-10
6,000
$10.3K
-10.2%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Nov 20, 2023.
  • -29.3% median (-34.6% mean) 90-day return after 5 previous buys.
  • The trade is 0.2% of the 2,491,908 shares held after it.
  • No other insider bought within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director DiMaio John Michael bought about $10.3K of MDAI on May 10, 2024, the largest insider purchase at the company on our record; 24 funds added in the latest 13F quarter.
DiMaio John Michael
BUY
2023-11-22 SECtraded 2023-11-20
2,000
$5.3K
-40.0%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Nov 16, 2023.
  • -37.0% median (-36.1% mean) 90-day return after 4 previous buys.
  • The trade is 0.1% of the 2,481,908 shares held after it.
  • No other insider bought within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DiMaio John Michael bought about $5.3K of MDAI on Nov 20, 2023; 24 funds added in the latest 13F quarter.
DiMaio John Michael
BUY
2023-11-22 SECtraded 2023-11-16
500
$1.3K
-40.0%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Nov 14, 2023.
  • -44.8% median (-38.3% mean) 90-day return after 3 previous buys.
  • The trade is 0.0% of the 2,479,908 shares held after it.
  • No other insider bought within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DiMaio John Michael bought about $1.3K of MDAI on Nov 16, 2023; 24 funds added in the latest 13F quarter.
DiMaio John Michael
BUY
2023-11-22 SECtraded 2023-11-14
355
$998
-40.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Sep 13, 2023.
  • -47.0% median (-47.0% mean) 90-day return after 2 previous buys.
  • The trade is 0.0% of the 2,479,408 shares held after it.
  • No other insider bought within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DiMaio John Michael bought about $998 of MDAI on Nov 14, 2023; 24 funds added in the latest 13F quarter.
DiMaio John Michael
BUY
2023-11-22 SECtraded 2023-09-13
198
$1.0K
-40.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 12, 2023.
  • The trade is 0.0% of the 2,479,053 shares held after it.
  • No other insider bought within 30 days.
  • 24 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider DiMaio John Michael bought about $1.0K of MDAI on Sep 13, 2023; 24 funds added in the latest 13F quarter.
6 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 1 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
24 funds bought in last quarter
below 68% of Medical Devices
Revenue
-33.6% year over year
below 92% of Medical Devices
Margin
-38.5% net margin
below 64% of Medical Devices
Buybacks
no share repurchases reported
Short interest
7.8% of the float short (float per yahoo 2026-10-27) · 14.4 days to cover · settled 2026-10-15
more than 76% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MDAI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-32.4%12M
-46%-24%-2%+21%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MDAI: institutional holders (13F)

13F holdings, latest reported quarter
VANGUARD CAPITAL MANAGEMENT LLC
994,410 sh
$1.7M
Highlander Partners, L.P.
900,000 sh
$1.6M
MARSHALL WACE, LLP
827,454 sh
$1.4M
BRIDGEWAY CAPITAL MANAGEMENT, LLC
287,000 sh
$496.5K
JANE STREET GROUP, LLC
226,319 sh
$391.5K

Congress trades in MDAI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MDAI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MDAI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$496.5K position · as of 2026-06-30
0.5%
iShares Micro-Cap ETF
$159.1K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$10.7K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$240.2K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$428.2K position · as of 2026-06-30
0.0%
Calamos Market Neutral Income Fund
$40.8K position · as of 2026-07-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 24 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

MDAI financials

Revenue growth
-33.6%
XBRL, annual
Net margin
-38.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$15.4M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-65.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Cash flow to debt
-1.09x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
n/a
average equity is zero or negative
Return on assets
-56.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
n/a
capital employed is zero or negative
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$46.1M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$19.6M$29.6M$18.1M$25.4M
Gross profit$8.9M$13.3M$7.9M$10.8M
Operating income-$8.6M-$6.6M-$13.0M-$2.6M
Net income-$7.6M-$15.2M-$20.9M-$2.9M
EPS (diluted)-0.29-0.85-1.48-0.22
Operating cash flow-$9.9M-$9.2M-$13.2M-$1.2M
Cash$15.4M$5.2M$4.8M$14.2M
Long-term debt$5.5M$2.8Mn/an/a
Buybacksn/an/an/a$250.5M
SEC XBRL, fiscal years, as known on 2026-10-28

MDAI Stock Sonar score 4/7 axes

Find similar shapesCompare

MDAI ranks highest on institutional and government (32nd percentile) and financial health (31st), and lowest on growth (8th), among Medical Devices peers.

Financial health
31
Inputs
  • Debt to equityequity is zero or negative, the ratio has no meaning
  • Cash flow to debt-1.09x · 31 pct, sector of 150
Growth
8
Inputs
  • Revenue growth, YoY-33.6% · 8 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
32
Inputs
  • Funds adding, latest quarter24 · 32 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
31
Inputs
  • Short interest, % of float+7.8% · 31 pct, sector of 241
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Insider conviction, US patents
  • Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; pre-tax loss, no effective tax rate to apply
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies